Opinion

Video

Final Thoughts on CSPC

Author(s):

Stephen J. Freedland, MD,Eleni Efstathiou, MD, PhD

Experts offer concluding remarks on castration-sensitive prostate cancer, sharing their perspectives on the evolving field and expressing their aspirations for future advancements in disease treatment.

Video content above is prompted by the following questions:

  • How do you foresee the early treatment paradigm for CSPC evolving in the coming years?
    • Are there other novel agents you're excited about in development?
    • How will their availability impact treatment sequencing strategies?
Related Videos
2 expert is featured in this series.
2 experts in this video
2 experts in this video
Related Content
Prostate Cancer
December 11th 2024

CAN-2409 Improves DFS in Intermediate/High-Risk Localized Prostate Cancer

Karen L. Reckamp, MD, professor, medicine, medical oncology director, Lung Institute, director, Division of Medical Oncology, associate director, Clinical Research, Cedars-Sinai Medical Center
June 20th 2024

Reckamp Discusses the Integration of Pragmatic Elements Into Oncology Clinical Trial Designs

FDA
December 5th 2024

FDA Grants Fast Track Designation to PT217 for Neuroendocrine Prostate Cancer

D. Ross Camidge, MD, PhD; B.J. Rimel, MD, assistant professor, obstetrics and gynecology, Cedars-Sinai, medical director, Cancer Clinical Trials Office, Cedars-Sinai Cancer Institute, health sciences associate clinical professor, Department of Obstetrics and Gynecology, University of California, Los Angeles
April 15th 2024

Camidge and Rimel on the Importance of Cultivating Inclusive Gynecologic Oncology Practices

Capivasertib Plus Abiraterone/ADT in PTEN-Deficient mHSPC | Image Credit: © Sebastian Kaulitzki - stock.adobe.com
November 25th 2024

Capivasertib Plus Abiraterone/ADT Improves rPFS in PTEN-Deficient mHSPC

FDA
November 21st 2024

FDA Accepts sNDA for Darolutamide Plus ADT in Metastatic Hormone-Sensitive Prostate Cancer